Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | GIPR | P48546 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035724 | 0.93 | PPARD (0.40) | HCRTR1HCRTR2PPARDPPARASMN1; SMN2 | |
| SCHEMBL6035533 | 0.91 | PTGDR2 (0.37) | PPARGPPARDPPARASMN1; SMN2PTGDR2 | |
| SCHEMBL6035190 | 0.90 | GCGR (0.35) | HCRTR1HCRTR2PPARDPPARAPTGDR2 | |
| SCHEMBL6035938 | 0.89 | PPARG (0.39) | PPARGPPARDPPARASMN1; SMN2PTGDR2 | |
| SCHEMBL6035540 | 0.86 | PPARG (0.40) | HCRTR1HCRTR2PPARGPPARDPPARA | |
| SCHEMBL6035550 | 0.85 | PPARG (0.40) | HCRTR1HCRTR2PPARGPPARDPPARA | |
| SCHEMBL6035092 | 0.85 | PTGDR2 (0.41) | PPARDPPARAPTGDR2GCGRGIPR | |
| SCHEMBL6036305 | 0.85 | PPARG (0.39) | HCRTR1HCRTR2PPARGPPARDPPARA | |
| SCHEMBL6035635 | 0.84 | PPARG (0.40) | HCRTR1HCRTR2PPARGPPARDPPARA | |
| SCHEMBL1633669 | 0.84 | PPARG (0.43) | HCRTR1HCRTR2PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | HCRTR1 215/4885HCRTR2 321/4885PPARG 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.